之江生物
(688317)
| 流通市值：34.03亿 | | | 总市值：34.03亿 |
| 流通股本：1.92亿 | | | 总股本：1.92亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 32,134,673.5 | 178,651,872.66 | 137,579,847.2 | 94,595,921.31 |
| 营业收入 | 32,134,673.5 | 178,651,872.66 | 137,579,847.2 | 94,595,921.31 |
| 二、营业总成本 | 51,227,131.69 | 160,107,466.65 | 130,299,732.01 | 52,452,433.4 |
| 营业成本 | 11,453,783.06 | 69,771,218.03 | 37,975,715.52 | 24,058,757.59 |
| 税金及附加 | 1,973,132.5 | 7,430,254.21 | 5,543,379.06 | 3,763,126.43 |
| 销售费用 | 12,034,590.16 | 55,586,644.23 | 49,172,418.13 | 34,657,982.04 |
| 管理费用 | 21,759,071.36 | 95,574,099.54 | 65,799,975.27 | 44,789,917.79 |
| 研发费用 | 13,572,425.59 | 58,783,335.09 | 39,074,589.3 | 24,401,863.08 |
| 财务费用 | -9,565,870.98 | -127,038,084.45 | -67,266,345.27 | -79,219,213.53 |
| 其中:利息费用 | 422,334.29 | 344,329.06 | 226,586.94 | 165,759.36 |
| 其中:利息收入 | 11,379,765.69 | 113,201,988.21 | 78,707,993.16 | 73,997,614.83 |
| 加:投资收益 | 153,937.45 | 57,120.46 | - | - |
| 资产处置收益 | - | 39,305.59 | 39,305.59 | 39,305.59 |
| 资产减值损失(新) | 1,966,131.1 | -162,849,610.59 | -25,242,978.05 | -14,494,431.28 |
| 信用减值损失(新) | 647,735.7 | -10,871,402.11 | -215,377.15 | -1,046,973.26 |
| 其他收益 | 1,393,510.38 | 9,414,247.24 | 8,193,886.12 | 3,541,272.3 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -14,931,143.56 | -145,665,933.4 | -9,945,048.3 | 30,182,661.26 |
| 加:营业外收入 | 428,526.74 | 2,067,210.93 | 67,466.24 | 36,473.64 |
| 减:营业外支出 | 917,167.33 | 6,972,188.25 | 1,066,383.99 | 922,052.06 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -15,419,784.15 | -150,570,910.72 | -10,943,966.05 | 29,297,082.84 |
| 减:所得税费用 | 597,548.85 | -23,108,787.01 | 2,065,622.89 | 3,292,120.33 |
| 六、净利润 | -16,017,333 | -127,462,123.71 | -13,009,588.94 | 26,004,962.51 |
| 持续经营净利润 | -16,017,333 | -127,462,123.71 | -13,009,588.94 | 26,004,962.51 |
| 归属于母公司股东的净利润 | -16,017,333 | -127,462,123.71 | -13,009,588.94 | 26,004,962.51 |
| (一)基本每股收益 | -0.08 | -0.67 | -0.07 | 0.14 |
| (二)稀释每股收益 | -0.08 | -0.67 | -0.07 | 0.14 |
| 八、其他综合收益 | -13,955.73 | -4,374,088.21 | -3,191,985.54 | -2,849,646.28 |
| 归属于母公司股东的其他综合收益 | -13,955.73 | -4,374,088.21 | -3,191,985.54 | -2,849,646.28 |
| 九、综合收益总额 | -16,031,288.73 | -131,836,211.92 | -16,201,574.48 | 23,155,316.23 |
| 归属于母公司股东的综合收益总额 | -16,031,288.73 | -131,836,211.92 | -16,201,574.48 | 23,155,316.23 |
| 公告日期 | 2025-04-30 | 2025-04-25 | 2024-10-30 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |